What is Tela Bio, Inc.'s earnings per share (EPS)?

Tela Bio, Inc. (TELA) reported diluted earnings per share of $-0.83 for fiscal year 2025. This represents a 37.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Tela Bio, Inc. Financials

TELA

Source SEC Filings (10-K/10-Q) Updated Mar 25, 2026 Currency USD FYE March

This page shows Tela Bio, Inc. (TELA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 24/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Tela Bio, Inc. has an operating margin of -42.0%, meaning the company retains $-42 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -49.2% the prior year.

Growth

Tela Bio, Inc.'s revenue surged 15.8% year-over-year to $80.3M, reflecting rapid business expansion. This strong growth earns a score of 60/100.

Leverage

Tela Bio, Inc. has elevated debt relative to equity (D/E of 8.82), meaning the company relies heavily on borrowed funds. This high leverage results in a low score of 0/100, reflecting increased financial risk.

Liquidity

With a current ratio of 4.20, Tela Bio, Inc. holds $4.20 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 83/100.

Cash Flow

While Tela Bio, Inc. generated -$28.2M in operating cash flow, capex of $448K consumed most of it, leaving -$28.7M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Tela Bio, Inc. generates a -615.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -133.0% the prior year.

Piotroski F-Score Weak

3/9

Tela Bio, Inc. passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality Low Quality

0.73x

For every $1 of reported earnings, Tela Bio, Inc. generates $0.73 in operating cash flow (-$28.2M OCF vs -$38.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-30.7x

Tela Bio, Inc. earns $-30.7 in operating income for every $1 of interest expense (-$33.8M vs $1.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$80.3M

YoY+15.8%

5Y CAGR+34.5%

Tela Bio, Inc. generated $80.3M in revenue in fiscal year 2025. This represents an increase of 15.8% from the prior year.

EBITDA

-$33.1M

YoY+1.1%

Tela Bio, Inc.'s EBITDA was -$33.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 1.1% from the prior year.

Net Income

-$38.8M

YoY-2.6%

Tela Bio, Inc. reported -$38.8M in net income in fiscal year 2025. This represents a decrease of 2.6% from the prior year.

EPS (Diluted)

$-0.83

YoY+37.6%

Tela Bio, Inc. earned $-0.83 per diluted share (EPS) in fiscal year 2025. This represents an increase of 37.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$28.7M

YoY+32.7%

Tela Bio, Inc. generated -$28.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 32.7% from the prior year.

Cash & Debt

$50.8M

YoY-3.5%

5Y CAGR-7.3%

Tela Bio, Inc. held $50.8M in cash against $55.7M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

45M

YoY+13.6%

5Y CAGR+25.4%

Tela Bio, Inc. had 45M shares outstanding in fiscal year 2025. This represents an increase of 13.6% from the prior year.

Margins & Returns

Gross Margin

67.7%

YoY+0.6pp

5Y CAGR+6.0pp

Tela Bio, Inc.'s gross margin was 67.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.6 percentage points from the prior year.

Operating Margin

-42.0%

YoY+7.2pp

5Y CAGR+96.7pp

Tela Bio, Inc.'s operating margin was -42.0% in fiscal year 2025, reflecting core business profitability. This is up 7.2 percentage points from the prior year.

Net Margin

-48.4%

YoY+6.2pp

5Y CAGR+109.7pp

Tela Bio, Inc.'s net profit margin was -48.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 6.2 percentage points from the prior year.

Return on Equity

-615.1%

YoY-482.1pp

5Y CAGR-556.4pp

Tela Bio, Inc.'s ROE was -615.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 482.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$9.2M

YoY+4.6%

5Y CAGR+16.7%

Tela Bio, Inc. invested $9.2M in research and development in fiscal year 2025. This represents an increase of 4.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$448K

YoY-54.7%

5Y CAGR+21.8%

Tela Bio, Inc. invested $448K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 54.7% from the prior year.

TELA Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$80.3M+15.8%	$69.3M+18.6%	$58.5M+41.1%	$41.4M+40.6%	$29.5M+61.8%	$18.2M
Cost of Revenue	$25.6M+13.9%	$22.4M+24.9%	$18.0M+32.4%	$13.6M+31.2%	$10.3M+55.0%	$6.7M
Gross Profit	$54.3M+16.9%	$46.5M+15.9%	$40.1M+48.3%	$27.0M+43.8%	$18.8M+67.5%	$11.2M
R&D Expenses	$9.2M+4.6%	$8.8M-8.4%	$9.6M+7.6%	$8.9M+32.5%	$6.7M+58.5%	$4.3M
SG&A Expenses	$15.7M+6.6%	$14.7M-1.1%	$14.9M+7.4%	$13.9M+11.3%	$12.5M+22.8%	$10.1M
Operating Income	-$33.8M+1.1%	-$34.1M+22.6%	-$44.1M-13.0%	-$39.0M-32.4%	-$29.5M-16.5%	-$25.3M
Interest Expense	$1.1M-79.2%	$5.3M+1.3%	$5.2M+28.9%	$4.1M+12.6%	$3.6M+0.9%	$3.6M
Income Tax	$230K+259.7%	-$144K	N/A	N/A	N/A	N/A
Net Income	-$38.8M-2.6%	-$37.8M+18.9%	-$46.7M-5.3%	-$44.3M-33.1%	-$33.3M-15.6%	-$28.8M
EPS (Diluted)	$-0.83+37.6%	$-1.33+34.8%	$-2.04+25.0%	$-2.72-18.3%	$-2.30-3.1%	$-2.23

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$20.7M+2.4%	$20.2M+9.1%	$18.5M+4.9%	$17.6M-6.9%	$19.0M+17.8%	$16.1M-3.1%	$16.6M-2.3%	$17.0M
Cost of Revenue	$6.6M+10.5%	$6.0M+1.4%	$5.9M-6.6%	$6.3M+5.5%	$6.0M+22.0%	$4.9M-4.8%	$5.2M-2.0%	$5.3M
Gross Profit	$14.0M-1.0%	$14.1M+12.7%	$12.5M+11.5%	$11.2M-12.7%	$12.9M+16.1%	$11.1M-2.3%	$11.3M-2.5%	$11.6M
R&D Expenses	$2.3M+6.6%	$2.2M-13.3%	$2.5M+25.2%	$2.0M-1.9%	$2.1M-11.0%	$2.3M-2.9%	$2.4M-10.9%	$2.7M
SG&A Expenses	$3.9M-4.3%	$4.1M+7.6%	$3.8M+6.9%	$3.6M-2.6%	$3.7M+1.7%	$3.6M-5.4%	$3.8M-5.5%	$4.1M
Operating Income	-$7.6M+16.8%	-$9.1M+13.3%	-$10.5M-25.4%	-$8.4M+10.8%	-$9.4M+19.1%	-$11.6M-139.7%	-$4.8M+60.7%	-$12.3M
Interest Expense	$1.2M+1.1%	$1.2M-2.5%	$1.2M-5.0%	$1.3M-4.5%	$1.3M+1.0%	$1.3M-0.1%	$1.3M-1.0%	$1.3M
Income Tax	N/A	$33K-36.5%	$52K	N/A	N/A	N/A	N/A	N/A
Net Income	-$8.6M+13.3%	-$9.9M+11.9%	-$11.3M-22.3%	-$9.2M+11.2%	-$10.4M+17.7%	-$12.6M-122.6%	-$5.7M+56.1%	-$12.9M
EPS (Diluted)	$-0.19+13.6%	$-0.22+12.0%	$-0.25	N/A	$-0.42+17.6%	$-0.51-121.7%	$-0.23	N/A

TELA Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$81.4M-6.0%	$86.6M+10.9%	$78.0M+15.0%	$67.9M+8.5%	$62.5M-27.7%	$86.5M
Current Assets	$75.6M-3.2%	$78.1M+8.8%	$71.7M+14.9%	$62.4M+5.7%	$59.1M-29.0%	$83.2M
Cash & Equivalents	$50.8M-3.5%	$52.7M+12.7%	$46.7M+11.2%	$42.0M-4.4%	$43.9M-40.9%	$74.4M
Inventory	$11.0M-13.8%	$12.8M-2.9%	$13.2M+11.6%	$11.8M+54.0%	$7.7M+96.0%	$3.9M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$75.1M+29.2%	$58.1M-1.8%	$59.2M+10.5%	$53.5M+26.2%	$42.4M+13.4%	$37.4M
Current Liabilities	$18.0M+15.2%	$15.6M-8.1%	$17.0M+36.8%	$12.4M+17.3%	$10.6M+60.1%	$6.6M
Long-Term Debt	$55.7M+35.3%	$41.1M+1.5%	$40.5M+1.5%	$39.9M+26.8%	$31.5M+2.2%	$30.8M
Total Equity	$6.3M-77.8%	$28.5M+50.7%	$18.9M+32.0%	$14.3M-28.8%	$20.1M-59.0%	$49.0M
Retained Earnings	-$397.6M-10.8%	-$358.7M-11.8%	-$320.9M-17.0%	-$274.2M-19.3%	-$229.9M-16.9%	-$196.7M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$61.6M-8.8%	$67.5M-12.6%	$77.3M-10.8%	$86.6M+63.3%	$53.0M-11.9%	$60.2M-16.2%	$71.8M-8.0%	$78.0M
Current Assets	$56.0M-7.7%	$60.7M-12.9%	$69.7M-10.7%	$78.1M+76.9%	$44.1M-13.7%	$51.1M-18.4%	$62.6M-12.7%	$71.7M
Cash & Equivalents	$29.7M-15.0%	$35.0M-18.3%	$42.8M-18.7%	$52.7M+204.4%	$17.3M-34.7%	$26.5M-28.7%	$37.1M-20.5%	$46.7M
Inventory	$11.6M+1.6%	$11.4M-16.0%	$13.5M+5.9%	$12.8M-6.0%	$13.6M+1.7%	$13.4M-1.7%	$13.6M+3.3%	$13.2M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$60.0M+2.9%	$58.4M-1.3%	$59.1M+1.7%	$58.1M-2.0%	$59.3M+3.4%	$57.3M-0.2%	$57.5M-2.9%	$59.2M
Current Liabilities	$17.0M-10.9%	$19.1M+15.3%	$16.5M+6.0%	$15.6M-7.5%	$16.9M+12.5%	$15.0M-1.3%	$15.2M-10.5%	$17.0M
Long-Term Debt	$41.5M+9.0%	$38.1M-7.8%	$41.3M+0.4%	$41.1M+0.4%	$41.0M+0.4%	$40.8M+0.4%	$40.7M+0.4%	$40.5M
Total Equity	$1.6M-83.0%	$9.2M-49.3%	$18.1M-36.3%	$28.5M+553.7%	-$6.3M-318.5%	$2.9M-80.0%	$14.4M-23.8%	$18.9M
Retained Earnings	-$388.5M-2.3%	-$379.9M-2.7%	-$370.0M-3.1%	-$358.7M-2.6%	-$349.5M-3.1%	-$339.1M-3.9%	-$326.6M-1.8%	-$320.9M

TELA Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$28.2M+32.2%	-$41.6M-1.8%	-$40.9M-0.3%	-$40.7M-33.9%	-$30.4M-24.4%	-$24.5M
Capital Expenditures	$448K-54.7%	$989K+61.9%	$611K-29.9%	$872K+39.1%	$627K+275.4%	$167K
Free Cash Flow	-$28.7M+32.7%	-$42.6M-2.7%	-$41.5M+0.4%	-$41.6M-34.0%	-$31.1M-26.1%	-$24.6M
Investing Cash Flow	$846K-81.0%	$4.5M+843.1%	-$599K+68.0%	-$1.9M-198.6%	-$627K-106.9%	$9.1M
Financing Cash Flow	$25.8M-40.2%	$43.1M-6.9%	$46.3M+13.3%	$40.9M+6883.2%	$585K-98.7%	$44.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$5.7M+27.7%	-$7.9M+18.7%	-$9.7M-29.1%	-$7.5M+16.2%	-$9.0M+16.0%	-$10.7M+25.6%	-$14.4M-30.2%	-$11.1M
Capital Expenditures	$211K+85.1%	$114K+256.3%	$32K-87.9%	$264K+116.4%	$122K-59.2%	$299K-1.6%	$304K+48.3%	$205K
Free Cash Flow	-$5.9M+26.1%	-$8.0M+17.8%	-$9.8M-25.2%	-$7.8M+14.4%	-$9.1M+17.2%	-$11.0M+25.1%	-$14.7M-30.5%	-$11.3M
Investing Cash Flow	$312K+52.9%	$204K+47.8%	$138K+172.6%	-$190K-55.7%	-$122K-282.1%	$67K-98.6%	$4.7M+2533.2%	-$193K
Financing Cash Flow	$24K+900.0%	-$3K+97.4%	-$116K-100.3%	$42.9M+43683.7%	$98K+2060.0%	-$5K-108.9%	$56K+154.5%	$22K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TELA Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	67.7%+0.6pp	67.1%-1.5pp	68.6%+3.3pp	65.3%+1.5pp	63.8%+2.2pp	61.7%
Operating Margin	-42.0%+7.2pp	-49.2%+26.2pp	-75.4%+18.8pp	-94.2%+5.8pp	-100.0%+38.8pp	-138.8%
Net Margin	-48.4%+6.2pp	-54.6%+25.2pp	-79.8%+27.1pp	-106.9%+6.0pp	-112.9%+45.2pp	-158.1%
Return on Equity	-615.1%-482.1pp	-133.0%+114.2pp	-247.1%+62.5pp	-309.6%-144.1pp	-165.6%-106.8pp	-58.7%
Return on Assets	-47.7%-4.0pp	-43.7%+16.1pp	-59.8%+5.5pp	-65.3%-12.1pp	-53.2%-19.9pp	-33.3%
Current Ratio	4.20-0.8	5.01+0.8	4.23-0.8	5.03-0.5	5.58-7.0	12.60
Debt-to-Equity	8.82+7.4	1.45-0.7	2.15-0.6	2.79+1.2	1.57+0.9	0.63
FCF Margin	-35.7%+25.7pp	-61.5%+9.5pp	-70.9%+29.5pp	-100.5%+4.9pp	-105.4%+29.8pp	-135.2%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	67.5%-2.3pp	69.8%+2.3pp	67.6%+4.0pp	63.6%-4.2pp	67.8%-1.0pp	68.8%+0.5pp	68.3%-0.1pp	68.4%
Operating Margin	-36.5%+8.5pp	-45.0%+11.6pp	-56.5%-9.2pp	-47.3%+2.1pp	-49.4%+22.5pp	-71.9%-42.8pp	-29.1%+43.2pp	-72.2%
Net Margin	-41.6%+7.6pp	-49.1%+11.7pp	-60.8%-8.6pp	-52.2%+2.5pp	-54.7%+23.6pp	-78.3%-44.2pp	-34.1%+41.7pp	-75.8%
Return on Equity	-552.5%-444.5pp	-108.0%-45.9pp	-62.2%-29.8pp	-32.4%	N/A	-439.0%-399.7pp	-39.4%+28.9pp	-68.3%
Return on Assets	-14.0%+0.7pp	-14.7%-0.1pp	-14.6%-3.9pp	-10.6%+8.9pp	-19.6%+1.4pp	-20.9%-13.1pp	-7.9%+8.6pp	-16.5%
Current Ratio	3.30+0.1	3.19-1.0	4.22-0.8	5.01+2.4	2.62-0.8	3.41-0.7	4.13-0.1	4.23
Debt-to-Equity	26.65+22.5	4.14+1.9	2.28+0.8	1.45+8.0	-6.53-20.8	14.22+11.4	2.83+0.7	2.15
FCF Margin	-28.7%+11.0pp	-39.7%+13.0pp	-52.7%-8.5pp	-44.2%+3.9pp	-48.0%+20.3pp	-68.3%+20.1pp	-88.5%-22.3pp	-66.2%

Similar Companies

Pulmonx Corp LUNG

$56.2M

Elutia Inc. ELUT

$50.1M

Xtant Medical XTNT

$68.9M

Apyx Medical Corporation APYX

$153.9M

Icecure Medical Ltd. ICCM

$24.4M

Frequently Asked Questions

What is Tela Bio, Inc.'s annual revenue?

Tela Bio, Inc. (TELA) reported $80.3M in total revenue for fiscal year 2025. This represents a 15.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Tela Bio, Inc.'s revenue growing?

Tela Bio, Inc. (TELA) revenue grew by 15.8% year-over-year, from $69.3M to $80.3M in fiscal year 2025.

Is Tela Bio, Inc. profitable?

No, Tela Bio, Inc. (TELA) reported a net income of -$38.8M in fiscal year 2025, with a net profit margin of -48.4%.

What is Tela Bio, Inc.'s EBITDA?

Tela Bio, Inc. (TELA) had EBITDA of -$33.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Tela Bio, Inc. have?

As of fiscal year 2025, Tela Bio, Inc. (TELA) had $50.8M in cash and equivalents against $55.7M in long-term debt.

What is Tela Bio, Inc.'s gross margin?

Tela Bio, Inc. (TELA) had a gross margin of 67.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Tela Bio, Inc.'s operating margin?

Tela Bio, Inc. (TELA) had an operating margin of -42.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Tela Bio, Inc.'s net profit margin?

Tela Bio, Inc. (TELA) had a net profit margin of -48.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Tela Bio, Inc.'s return on equity (ROE)?

Tela Bio, Inc. (TELA) has a return on equity of -615.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Tela Bio, Inc.'s free cash flow?

Tela Bio, Inc. (TELA) generated -$28.7M in free cash flow during fiscal year 2025. This represents a 32.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Tela Bio, Inc.'s operating cash flow?

Tela Bio, Inc. (TELA) generated -$28.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Tela Bio, Inc.'s total assets?

Tela Bio, Inc. (TELA) had $81.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Tela Bio, Inc.'s capital expenditures?

Tela Bio, Inc. (TELA) invested $448K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Tela Bio, Inc. spend on research and development?

Tela Bio, Inc. (TELA) invested $9.2M in research and development during fiscal year 2025.

How many shares does Tela Bio, Inc. have outstanding?

Tela Bio, Inc. (TELA) had 45M shares outstanding as of fiscal year 2025.

What is Tela Bio, Inc.'s current ratio?

Tela Bio, Inc. (TELA) had a current ratio of 4.20 as of fiscal year 2025, which is generally considered healthy.

What is Tela Bio, Inc.'s debt-to-equity ratio?

Tela Bio, Inc. (TELA) had a debt-to-equity ratio of 8.82 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Tela Bio, Inc.'s return on assets (ROA)?

Tela Bio, Inc. (TELA) had a return on assets of -47.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Tela Bio, Inc.'s cash runway?

Based on fiscal year 2025 data, Tela Bio, Inc. (TELA) had $50.8M in cash against an annual operating cash burn of $28.2M. This gives an estimated cash runway of approximately 22 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Tela Bio, Inc.'s Piotroski F-Score?

Tela Bio, Inc. (TELA) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Tela Bio, Inc.'s earnings high quality?

Tela Bio, Inc. (TELA) has an earnings quality ratio of 0.73x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Tela Bio, Inc. cover its interest payments?

Tela Bio, Inc. (TELA) has an interest coverage ratio of -30.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Tela Bio, Inc.?

Tela Bio, Inc. (TELA) scores 24 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.